Allopurinol use and risk of multiple sclerosis
Individuals diagnosed with MS had significantly lower allopurinol use in the five years preceding their diagnosis, suggesting an inverse relationship between uric acid levels and MS risk. Reduced uric acid levels may be associated with early MS development, possibly due to its antioxidant properties or metabolic changes. Alternatively, these findings suggest a possible protective effect of allopurinol against MS, warranting further investigation.
Authors
- Melinda Magyari (ORCID: https://orcid.org/0000-0002-0972-5222)
- Josefine Windfeld‐Mathiasen (ORCID: https://orcid.org/0000-0001-6821-4898)
- Henrik Horwitz (ORCID: https://orcid.org/0000-0001-6436-1567)
- Elisabeth Framke (ORCID: https://orcid.org/0000-0002-5702-3954)
- Ida M. Heerfordt (ORCID: https://orcid.org/0000-0002-6130-875X)
Institutions
- Frederiksberg Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Danish Multiple Sclerosis Center (DK)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.msard.2025.106299
- Citations
- 4
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.89